Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 33%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is expected to have a relatively easy path to regulatory approval thanks to a recent FDA guidance that aligns with the company's phase 3 trial design. The company's financials are strong, with a significant amount of cash on hand and a positive outlook for peak revenues of $3.8 billion in 2037. The company's drug, COMP360, has shown strong potential in clinical trials and is expected to have significant demand from prescribers, with 90% indicating they would prescribe it within the first year of availability. The stock's currently undervalued and we expect a $21 price target, which is based on a discounted cash flow analysis and includes credit for the company's potential expansion into treating PTSD.

Bears say

Compass Pathways is currently overvalued with a total firm value of $8.8 billion, based on a discounted cash flow methodology. This is mainly due to the high probability of success assigned for its treatment of treatment-resistant depression and PTSD, and the 12% discount rate used to calculate cash flows. However, there are numerous risks, such as clinical development and competitor risks, as well as regulatory and commercialization risks, that could affect the company's ability to achieve its price target of $65.

COMPASS Pathways (CMPS) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 33% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 12 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Sep 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.